Illinois Endotronix Acquired by Edwards Lifesciences in Major Healthcare Deal

Illinois Endotronix Acquired by Edwards Lifesciences in Major Healthcare Deal

by John Conrad| Jul 24, 2024| NewsBrief

In a significant development for Illinois' healthcare technology sector, Endotronix has been acquired by Edwards Lifesciences, a global leader in patient-focused innovations for structural heart disease and critical care monitoring. This acquisition marks a major milestone for Endotronix, which has grown from its humble beginnings in Peoria in 2007 to become a leader in heart failure management solutions.

Endotronix's journey is a testament to the innovation and perseverance fostered in Illinois' healthcare ecosystem. The company has developed groundbreaking technology to address the pressing needs of heart failure patients, culminating in the recent FDA approval of their Cordella system. This implantable pulmonary artery pressure sensor allows for early, targeted therapeutic intervention in heart failure patients, potentially improving outcomes and quality of life for millions.

The acquisition by Edwards Lifesciences, with an aggregate upfront purchase price of approximately $1.2 billion for both Endotronix and another company, JenaValve Technology, underscores the value and potential of Endotronix's innovations. This move is expected to expand Edwards' structural heart portfolio into the critical area of heart failure management, addressing significant unmet needs in patient care.

John Conrad, president and CEO of iBIO, commented on the significance of this acquisition for Illinois:

"Endotronix's acquisition by Edwards Lifesciences is a remarkable success story for Illinois' life sciences ecosystem. Founded in Peoria and nurtured within our state, Endotronix has grown from a promising startup to a leader in heart failure management solutions. This acquisition not only validates the innovative spirit and technical expertise fostered in Illinois but also signals to the global healthcare community that our state is a fertile ground for groundbreaking medical technologies. Endotronix's journey showcases the potential for future growth in our biotech and medtech sectors, attracting more investment, talent, and opportunities to Illinois. As we celebrate this milestone, we're inspired by the possibilities it opens up for other emerging companies in our state. Endotronix's success paves the way for Illinois to become an even more prominent hub for life sciences innovation, promising a bright future for our industry and, most importantly, for patients worldwide who will benefit from these advancements."

For Endotronix, this acquisition represents not just a financial win but also an opportunity to accelerate the reach and impact of their technology. By joining forces with Edwards Lifesciences, Endotronix's innovations are poised to benefit from increased resources, broader distribution channels, and synergies with Edwards' existing portfolio of cardiac care solutions.

The success of Endotronix serves as an inspiring example of how companies rooted in Illinois can grow to make a global impact in healthcare. From its founding in Peoria to this landmark acquisition, Endotronix has demonstrated the potential for innovation and growth within the state's medical technology sector.

Looking ahead, the integration of Endotronix into Edwards Lifesciences' operations holds promise for continued advancements in heart failure management. With a CMS national coverage determination for the Cordella system expected in early 2025, the stage is set for potentially wider adoption and accessibility of this life-changing technology.

The acquisition is subject to customary closing conditions, including regulatory approvals, but is anticipated to close in the near future. As Endotronix enters this new chapter, the healthcare community in Illinois and beyond watches with keen interest, expecting further innovations and improvements in patient care to emerge from this union.

Congratulations to the entire Endotronix team on this remarkable achievement. Their dedication to improving heart failure care has not only led to this significant acquisition but has also positioned Illinois as a hub for medical technology innovation. As Endotronix begins its journey as part of Edwards Lifesciences, the healthcare community looks forward to the continued collaboration and advancements that will undoubtedly arise from this partnership.

Read the press release

This article was originally published on iBIO NewsBrief. Gain a head start on your day with iBIO NewsBrief. Subscribe to receive top industry headlines delivered straight to your inbox.